Paradigm Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Paradigm Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-126,200	Closed	-$1.22M	–	920
2014 Q2	$1.22M	Sell	126,200 -4,800	-4%	-$42.8K	0.16%	169
2014 Q1	$1.09M	Sell	131,000 -10,100	-7%	-$86.6K	0.15%	181
2013 Q4	$1.19M	Buy	141,100 +14,700	+12%	+$124K	0.18%	174
2013 Q3	$1.01M	Buy	126,400 +49,400	+64%	+$397K	0.16%	173
2013 Q2	$594K	Buy	+77,000	New	+$600K	0.1%	234

Other funds holding PDLI

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Paradigm Asset Management's PDLI Position: Q3 2014 in Review

Paradigm Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2014, closing a stake of 126,200 shares — an estimated $1.22M sold.

Paradigm Asset Management first reported a position in PDLI in Q2 2013 and held it in 5 quarters. The position peaked at $1.22M in Q2 2014. 231 funds tracked by Wall St. Rank hold PDLI as of Q3 2014.

Paradigm Asset Management reported no remaining PDL BioPharma, Inc. position as of Q3 2014 after selling out during the quarter.
Paradigm Asset Management sold 126,200 PDL BioPharma, Inc. shares in Q3 2014, an estimated $1.22M.
Paradigm Asset Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 5 quarters.
Paradigm Asset Management's PDL BioPharma, Inc. position peaked at $1.22M in Q2 2014.
231 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2014.

Based on Paradigm Asset Management's 13F filing for Q3 2014, filed 12 Nov 2014.